Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models

Based on the previously described roles of doxorubicin in immunogenic cell death, both doxorubicin and liposomal doxorubicin (Doxil) were evaluated for their ability to boost the antitumor response of different cancer immunotherapies including checkpoint blockers (anti–PD-L1, PD-1, and CTLA-4 mAbs)...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Jonathan Rios-Doria, Nicholas Durham, Leslie Wetzel, Raymond Rothstein, Jon Chesebrough, Nicholas Holoweckyj, Wei Zhao, Ching Ching Leow, Robert Hollingsworth
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Elsevier 2015-08-01
Reeks:	Neoplasia: An International Journal for Oncology Research
Online toegang:	http://www.sciencedirect.com/science/article/pii/S1476558615001001
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!